Study Of INCA 0186 In Subjects With Advanced Solid Tumors

Study Overview

Study of INCA 0186 in Subjects With Advanced Solid Tumors

This is an open-label, nonrandomized, multicenter, dose escalation, and dose expansion first-in human (FIH) Phase 1 study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCA00186 when given alone or in combination with INCB106385 and/or retifanlimab in participants with specific advanced solid tumors; squamous cell carcinoma of the head and neck (SCCHN) and specified gastrointestinal (GI) malignancies have been selected as indications of interest for this study. Participants with CD8 T-cell-positive tumors will be selected as these tumors are more likely to respond to immunotherapy.

N/A

Advanced Solid Tumors
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Gastrointestinal (GI) Malignancies

DRUG: INCA00186
DRUG: Retifanlimab
DRUG: INCB106385

INCA 0186-101
2021-001263-24 (EUDRACT_NUMBER Identifier) (EUDRACT_NUMBER: )

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2021-07-22	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2025-08-25
First Submitted that Met QC Criteria 2021-07-27	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ESTIMATED) 2025-09-02
First Posted (ESTIMATED) 2021-08-04	Results First Posted N/A	Last Verified 2025-08

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Non Randomized

Interventional Model:
Factorial

Masking:
None

Arms and Interventions

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Treatment Group A Dose Escalation and Expansion INCA00186 will be administered as monotherapy every 2 or every 4 weeks.	DRUG: INCA00186 INCA00186 will be administered every 2 weeks or 4 weeks as per protocol
EXPERIMENTAL: Treatment Group B1 Dose Escalation and Expansion INCA00186 will be administered in combination with retifanlimab. INCA00186 will be administered every 2 or 4 weeks and retifanlimab will be administered every 4 weeks.	DRUG: INCA00186 INCA00186 will be administered every 2 weeks or 4 weeks as per protocol DRUG: Retifanlimab Retifanlimab will be administered every 4 weeks as per protocol
EXPERIMENTAL: Treatment Group B2 Dose Escalation and Expansion INCA00186 will be administered in combination with INCB106385. INCA00186 will be administered every 2 or 4 weeks and INCB106385 will be administered once or twice daily.	DRUG: INCA00186 INCA00186 will be administered every 2 weeks or 4 weeks as per protocol DRUG: INCB106385 INCB106385 will be administered orally once or twice a day.
EXPERIMENTAL: Treatment Group C Dose Escalation and Expansion INCA00186 will be administered in combination with retifanlimab and INCB106385. INCA00186 will be administered every 2 to 4 weeks, retifanlimab every 4 weeks and INCB106385 once or twice daily.	DRUG: INCA00186 INCA00186 will be administered every 2 weeks or 4 weeks as per protocol DRUG: Retifanlimab Retifanlimab will be administered every 4 weeks as per protocol DRUG: INCB106385 INCB106385 will be administered orally once or twice a day.

Primary Outcome Measures	Measure Description	Time Frame
Evaluation of the safety and tolerability of INCA00186 as monotherapy and in combination with retifanlimab and/or INCB106385 as measured by the number of participants with adverse eventsductions and withdrawal of treatment due to AEs		90 days after study completion totaling up to 27 months
Evaluation of Dose-Limiting Toxicity (DLTs) of INCA00186 as monotherapy and in combination with retifanlimab and/or INCB106385 as measured by safety events during treatment		90 days after study completion totaling up to 27 months
Evaluation of Recommended Dose for Expansion (RDE) of INCA00186 as monotherapy and in combination with retifanlimab and/or INCB106385 as measured by safety, PK and PD data		90 days after study completion totaling up to 27 months

Secondary Outcome Measures	Measure Description	Time Frame
Determination of PK parameter Maximum Observed Plasma Concentration (Cmax) for INCA00186		Cycle 1 days 1, 2, 8, 15, 22; Cycle 2 days 1, 8; Day 1 of every other cycle starting at Cycle 4 (ie, Cycle 4 day 1, Cycle 6 day 1, etc; each cycle is 28 days) + 30 day follow-up; approximately 24 months
Determination of PK parameter of Time to Maximum Plasma Concentration (tmax) for INCA00186		Cycle 1 days 1, 2, 8, 15, 22; Cycle 2 days 1, 8; Day 1 of every other cycle starting at Cycle 4 (ie, Cycle 4 day 1, Cycle 6 day 1, etc; each cycle is 28 days) + 30 day follow-up; approximately 24 months
Determination of PK parameter of concentration at the end of the dosing interval (Ctau) for INCA00186		Cycle 1 days 1, 2, 8, 15, 22; Cycle 2 days 1, 8; Day 1 of every other cycle starting at Cycle 4 (ie, Cycle 4 day 1, Cycle 6 day 1, etc; each cycle is 28 days) + 30 day follow-up; approximately 24 months
Determination of PK parameter of area under the plasma or serum concentration-time curve (AUC) for INCA00186		Cycle 1 days 1, 2, 8, 15, 22; Cycle 2 days 1, 8; Day 1 of every other cycle starting at Cycle 4 (ie, Cycle 4 day 1, Cycle 6 day 1, etc; each cycle is 28 days) + 30 day follow-up; approximately 24 months
Determination of PK parameter of total clearance (CL) for INCA00186		Cycle 1 days 1, 2, 8, 15, 22; Cycle 2 days 1, 8; Day 1 of every other cycle starting at Cycle 4 (ie, Cycle 4 day 1, Cycle 6 day 1, etc; each cycle is 28 days) + 30 day follow-up; approximately 24 months
Determination of PK parameter of volume of distribution (Vz) for INCA00186		Cycle 1 days 1, 2, 8, 15, 22; Cycle 2 days 1, 8; Day 1 of every other cycle starting at Cycle 4 (ie, Cycle 4 day 1, Cycle 6 day 1, etc; each cycle is 28 days) + 30 day follow-up; approximately 24 months
Determination of PK parameter half-life (t1/2) for INCA00186		Cycle 1 days 1, 2, 8, 15, 22; Cycle 2 days 1, 8; Day 1 of every other cycle starting at Cycle 4 (ie, Cycle 4 day 1, Cycle 6 day 1, etc; each cycle is 28 days) + 30 day follow-up; approximately 24 months
Intratumoral effect of INCA0186 on CD73 enzymatic activity		2 biopsy samples will be taken: pre-treatment and on-treatment on Cycle 1 Day 22 (for every 2 week INCA00186 dosing group) or Cycle 2 Day 8 (for every 4 week INCA00186 dosing group); each cycle is 28 days; sampling will be taken within 2 months.
Objective Response Rate (ORR) by radiographic disease assessment		Baseline through end of study up, to 24 months
Disease Control Response (DCR) determined by radiographic disease assessment		Baseline through end of study, up to 24 months
Duration of Response (DOR) from earliest date of disease response until earliest date of disease progression as determined by radiographic disease assessment, or death if occurring sooner than progression		Baseline through end of study, up to 24 months

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

Ability to comprehend and willingness to sign a written ICF for the study.
Male or female participant aged 18 years or older inclusive at the time of signing the ICF.
Must be willing and able to conform to and comply with all Protocol requirements
Willingness to undergo pre- and on-treatment tumor biopsy.
Have CD8 T-cell-positive tumors
ECOG performance status 0 or 1.
Measurable disease according to RECIST v1.1.
Participants with SCCHN: Participants with histologically or cytologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx not amenable to local therapy with curative intent (surgery or radiation with or without chemotherapy).
Participants with specified GI malignancies: Histologically or cytologically confirmed advanced or metastatic colorectal (CRC), gastric/gastroesophageal junction (GEJ) cancer, hepatocellular carcinoma (HCC), pancreatic ductal adenocarcinoma (PDAC), or squamous carcinoma of the anal canal (SCAC).
Participants should have disease progression after treatment with available therapies, including anti-PD-(L)1 therapy (if applicable), that are known to confer clinical benefit or who are intolerant to or ineligible for standard treatment. Prior anti-PD-(L)1 therapy should not have been discontinued because of intolerance.
For participants to be enrolled in cohorts including INCB106385: The ability to swallow oral medication.
Willingness to avoid pregnancy or fathering children

Clinically significant cardiac disease, unstable angina, acute myocardial infarction within 6 months of Cycle 1 Day 1, and New York Heart Association Class III or IV congestive heart failure.
History or presence of an ECG abnormality that, in the investigator's opinion, is clinically meaningful.
Known active CNS metastases and/or carcinomatous meningitis.
Participants who have active or inactive autoimmune disease or syndrome (eg, rheumatoid arthritis, moderate or severe psoriasis, multiple sclerosis, inflammatory bowel disease) that has required systemic treatment in the past 2 years or who are receiving systemic therapy for an autoimmune or inflammatory disease (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs).
Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (doses > 10 mg daily of prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days before the first dose of study treatment.
Known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of the first dose of study treatment with the exception of cured basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy, or cancers from which the participant has been disease free > 1 year after treatment with curative intent.
Participants with protocol specified exclusionary hematology, hepatic, renal and coagulation laboratory values at screening.

Evidence of interstitial lung disease, history of interstitial lung disease, or active noninfectious pneumonitis.
Immune-related toxicity during prior immune therapy for which permanent discontinuation of therapy is recommended, OR any immune-related toxicity requiring intensive or prolonged immunosuppression to manage.
Prior treatment with any adenosine pathway targeting drugs.
Any prior chemotherapy, biological therapy, or targeted therapy to treat the participant's disease within 5 half-lives or 28 days (whichever is shorter) before the first dose of study treatment.
Any prior radiation therapy within 28 days before the first dose of study treatment.
Undergoing treatment with another investigational medication or having been treated with an investigational medication within 5 half-lives or 28 days (whichever is shorter) before the first dose of study treatment.
For participants to be enrolled in cohorts including INCB106385: concomitant treatment with strong CYP3A4 inhibitors or inducers.
Receipt of a live virus vaccine within 30 days of the first dose of study treatment.
Infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week of the first dose of study treatment.
Known or suspected SARS-CoV-2 infection at the time of enrollment.
Active HBV or HCV infection that requires treatment. HBV-DNA and HCV-RNA must be undetectable. Participants who have cleared a prior HBV infection (defined as HBsAg negative, HBsAg antibody positive, and anti-HBc antibody positive) are eligible for the study.
Known history of HIV (HIV 1/2 antibodies).
History of organ transplant, including allogeneic stem-cell transplantation or CAR-T cell therapy.
Known hypersensitivity or severe reaction to any component of study drug(s) or formulation components.
For participants to be enrolled in cohorts including INCB106385: Inability to swallow food or any concomitant condition of the upper GI tract that precludes administration of oral medications.
Is pregnant or breastfeeding.
Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study treatment and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
The following participants are excluded in France: vulnerable populations according to article L.1121-6 of the French Public Health Code and adults under legal protection or who are unable to express their consent per article L.1121-8 of the French Public Health Code.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

STUDY_DIRECTOR: Ilona Rybicka, MD, Incyte Corporation

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

PatientS

Caregivers

Clinical Trial Record

Study Overview

Study Record Dates

Study Plan

Design Details

Contacts and Locations

Participation Criteria

Collaborators and Investigators

Publications

About

Events

Fundraising

Contact Us

Learn

Resources

Patients

Caregivers

Learn

Resources

PatientS

Caregivers

Clinical Trial Record